CClinicalTrials.gg
CompletedNCT04702334Updated Jan 8, 2021

Hyaluronic Acid for Residual Periodontal Pockets Adjunctive Treatment

An interventional study of Hyaluronic Acid and Lidocain in Periodontitis, sponsored by University of Roma La Sapienza. Completed. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-08.

Sponsored by University of Roma La Sapienza · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 11 months after the study started (first participant enrolled Jan 2016, registered Dec 2020).
Phase
Not applicable
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Objective: To evaluate the adjunctive effect of hyaluronic acid (HA) gel in the treatment of residual periodontal pockets over a 12-month period.

Materials and Methods: Periodontal patients enrolled in maintenance and presenting at least one periodontal pocket 5-9 mm of depth in the anterior area were recruited from six university-based centers. Each patient was randomly assigned to control treatment with professional mechanical plaque removal (PMPR) and local placebo application or test treatment with the adjunctive use of HA to PMPR. Clinical parameters [i.e. probing depth (PD), bleeding on probing (BoP), plaque score, recession (REC), and clinical attachment loss (CAL)] and microbiological samples for the investigation of the total bacterial count (TBC) and presence of specific bacterial strains (Porphyromonas gingivalis, Treponema denticola, Tannerella forsythia, Fusobacterium nucleatum) were taken at baseline and every 3 months, until study termination. PD was determined as the primary outcome variable.

Read the detailed description

Population A total of 144 patients were enrolled from 6 university clinical centers (Sapienza University of Rome, Department of Periodontology, Rome, Italy ; University of Rijeka, School of Dental Medicine, Rijeka, Croatia; University of Zagreb, Department of Periodontology, Zagreb, Croatia; Jagiellonian University, Dental Institute, Krakow, Poland; Medical University of Sofia, Faculty of Dentistry, Sofia, Bulgaria; Medical University of Plovdiv, Faculty of Dentistry, Plovdiv, Bulgaria). The extension in time from patient recruitment to end of the protocol was January 2016 to November 2018.

The sample size was determined considering the patient level as statistical unit and probing depth (PD) as the primary outcome measure. In order to detect a mean difference of 1 mm of PD between groups with a standard deviation of 1 mm, maintaining a power of 85%, a significance level (alpha) of 0.05 and a drop-out of 25%, 12 participants per group in each center were required.

The ethical committees of each center approved the protocol of this study. The protocol followed the ethical principles of Helsinki Declaration on the good conduct of clinical trials. All patients were thoroughly informed on the treatment details and on the possibility of being excluded from the study if missing any of the 3 months follow-up appointments or showing poor compliance in general. After verbally accepting the conditions of the protocol, patients signed the informed consent prior to study initiation. Figure 1 shows step by step the study protocol that each patient followed.

Study design, randomization, allocation concealment and blinding This study was projected as a controlled randomized multicenter triple blinded 12-month clinical trial to compare the treatment of residual periodontal pockets using standard non-surgical mechanical debridement with and without hyaluronic acid gel. The detailed description of the treatment and evaluation is described in the following paragraphs.

The operators were trained and calibrated on treatment application and on PD measurement prior to study initiation. A preliminary session of PD measurements on 3 periodontal patients revealed an intra-class correlation coefficient ≥ 0.75 for each operator and among different operators.

An electronic web-based online randomization system was used for this study including a simulation version of the software for operator training prior to trial initiation. This system had been approved by the Austrian Agency for Health and Food Safety (AGES). The system parameters were set to randomization block size of 4, treatment code selection to random, using 24 treatment codes per center, and using minimization method. Centers were included as a factor for randomization process with assignment probability of 0,125 for each center (8 centers x 0,125 = 1.0) as the randomization ratio was 1:1 corresponding to treatment/ control allocation ratio.

Each operator had a username and password to perform the randomization process for each patient. An accurate audit trail showed each user log entry consisting of login-ID, center number, investigator name, event code, date, and time of which the event occurred. The system had trial specific features (role-based access control) where trial coordinators could manage each user assigned specific role determining the user's access rights. For the present study, the investigators role was to randomize without the ability to view the trial design or randomization design. The access to full control, view randomizations, un-blind randomization, was only granted to the independent trial coordinator.

Furthermore, the system provided high flexibility and security including verification for the personal email for each investigator to guarantee that each investigator will perform the randomization personally, setting a pre-defined randomization limit, the possibility to include multiple users under each center, and an effective email notification and confirmation upon each randomization performed. All transactions on the system were logged and an audit trail could be analyzed at any time by the trial monitor.

The allocation concealment was done by means of independent computerized randomization sequence process which can only be accessed by the independent trial coordinator. The investigators were provided with online login and were instructed to perform the randomization only after finishing the baseline measurements and mechanical debridement of selected tooth. To ensure that, investigators were requested to write down the exact time on provided case report forms upon finishing debridement. The computerized time stamp, electronic logs of sent allocation served as a method for monitoring allocation concealment. Furthermore, having the randomization as parallel with stratified (stratification by center) permuted blocks, served as a second layer of preventing knowledge of upcoming patient's assignment.

Clinical operators were kept blind until the moment of adjunctive treatment application allocated by the randomizer. Patients remained blinded during the entire follow-up. Microbiological evaluation and statistical interpretation of the results were made blinded on the treatment performed.

Treatment procedure Each center was provided with the same amount of HA , Eppendorf tubes, curettes , tooth paste , tooth brushes ** and interdental brushesǁ. Patients were instructed to use the modified Bass technique for brushing twice daily with the provided toothpaste free of chlorhexidine and to use the interdental brush once daily. They were instructed not to use any type of mouthwash.

All patients underwent a full mouth debridement completed within 48h in two consecutive visits. The debridement was performed using ultrasonic devices followed by curettes for all pockets of more than 4 mm. The ultrasonic treatment was repeated to ensure all surfaces were clean, followed by polishing.

At reevaluation, a tooth entering the inclusion criteria was selected. After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of hyaluronic acid gel for the test group and local administration of anesthetic for the control group. The tip of blunt application needle mounted on the syringe containing HA was delicately inserted in the pocket until resistance was felt. The injection was performed until the remnants started getting out of the pocket. Patients were advised not to drink or eat for 2 hours. This adjunctive treatment was performed at baseline and at the 3 months control. For both groups cleaning of supragingival tooth deposits and polishing was repeated at 3, 6, 9, and 12 months.

Statistical analysis Numerical variables were reported as median (IQR) while categorical variables were reported as frequency (percentage). McNemar test was used to test for differences in proportions between time points within groups and Chi-squared test was used for differences in proportions between groups. For numerical variables, time-points differences were assessed with the Kruskal-Wallis test and pairwise comparisons were performed with Mann-Whitney U test and Wilcoxon signed rank test (for unrelated and related measurements respectively). Holms correction was used to adjust for multiple comparisons. A significance level of 0.05 was used for all statistical tests. All the analytical tests were performed using the statistical software R (version 3.6.0).

02

Conditions studied

  • Periodontitis

Keywords

  • hyaluronic acid
  • periodontitis
  • periodontal therapy
  • residual pockets
03

In context

Periodontitis

1,635 studies on the registry are indexed under Periodontitis; 327 are open to participants now.

This study's enrollment of 144 is above the median of 45 across 1,191 interventional studies indexed under Periodontitis.

Browse Periodontitis studies →

Lead sponsor

University of Roma La Sapienza is the lead sponsor of 388 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • at least 18 years of age
  • systemically healthy,
  • smoking less than 10 cigarettes/day
  • having been treated for periodontitis but with at least one single residual pocket of 5-9mm of depth located in the anterior area (incisors and canines)
  • full-mouth bleeding score (FMBS)
  • full-mouth plaque score (FMPS) less than 20%
  • showing a good compliance to oral hygiene instructions

Exclusion criteria

Exclusion Criteria:

  • were pregnancy/lactation
  • use of antibiotics in the last 3 months for a period of two weeks or more
  • use of drugs causing gingival hyperplasia
  • use of corticosteroids or anti-inflammatory drugs for a period of two weeks or more
  • presence of diseases knowing to influence the wound healing/tissue response
  • thyroid or pituitary gland malfunction or abnormal hormonal levels
  • hyaluronic acid contraindications
  • subjects under anticoagulant treatment
  • use of systematic antibiotics for endocarditis prophylaxis
  • radiation therapy in head and neck area
  • use of bisphosphonate drugs prescribed for patients with osteoarthritis
  • tooth mobility.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    Hyaluronic acid

    After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of hyaluronic acid gel . This adjunctive treatment was performed at baseline and at the 3 months control.

    Drug: Hyaluronic Acid

  • Placebo comparator
    Lidocaine

    After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of anesthetic. This adjunctive treatment was performed at baseline and at the 3 months control.

    Drug: Lidocain

Interventions

  • DrugHyaluronic Acid

    After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of hyaluronic acid gel for the test group . The tip of blunt application needle mounted on the syringe containing HA was delicately inserted in the pocket until resistance was felt. The injection was performed until the remnants started getting out of the pocket.This adjunctive treatment was performed at baseline and at the 3 months control.

    Also known as: Hyadent® BG, BioScience GmbH, Germany

  • DrugLidocain

    After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of anesthetic for the control group. The tip of blunt application needle mounted on the syringe containing HA was delicately inserted in the pocket until resistance was felt. The injection was performed until the remnants started getting out of the pocket.This adjunctive treatment was performed at baseline and at the 3 months control.

    Also known as: Xylocaine® Dental

06

What researchers measure

Primary outcomes

  1. PD (change is being assessed)

    probing depth (PD) measured with periodontal probe in mm

    Time frame: at baseline and at 3, 6, 9, and 12 months after being treated

Secondary outcomes

  1. BoP(change is being assessed)

    bleeding on probing measured after probing as dichotomous parameter

    Time frame: at baseline and at 3, 6, 9, and 12 months after being treated

  2. Dental plaque(change is being assessed)

    dental plaque measured with periodontal probe as dichotomous parameter

    Time frame: at baseline and at 3, 6, 9, and 12 months after being treated

  3. REC(change is being assessed)

    gingival recession measured with periodontal probe in mm

    Time frame: at baseline and at 3, 6, 9, and 12 months after being treated

Other outcomes

  1. microbiological measurements(change is being assessed)

    Total bacterial count, Porphyromonas gingivalis, Treponema denticola, Tannerella forsythia, Fusobacterium nucleatum

    Time frame: at baseline and at 3, 6, 9, and 12 months after being treated

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Only IPD that underlie results in the publication

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04702334
Lead sponsor
University of Roma La Sapienza
Collaborators
University of Rijeka, University of Zagreb, Jagiellonian University, Medical University of Sofia, University of Bern, Plovdiv Medical University
Responsible party
Andrea Pilloni MD DDS MS (Associate professor of Periodontology, University of Roma La Sapienza) — Principal investigator
First posted
Jan 8, 2021
Start date
Jan 2016
Primary completion
Nov 2018
Completion
Nov 2018
Last update
Jan 8, 2021

Study contacts

Blerina Zeza, DDS,MS,PhD
study director · University of Rome
Andrea Pilloni, DDS,Msc
principal investigator · University of Rome

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion